@dansfera: Is the golden age of CROs coming to an end? Big Pharma is starting to question the outsourcing model, especially with ongoing frustrations over site payments and operational bottlenecks. When handling it in-house becomes more economically advantageous and efficient, the shift away from outsourcing seems inevitable. It’s a massive pivot in the industry worth watching. #biotech #bigpharma #clinicaltrials #cro #pharmaceuticals